Boundless Bio, Inc.
BOLD
$1.15
-$0.02-1.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.69% | -3.26% | 4.02% | 38.60% | 46.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.39% | -19.06% | -12.02% | 2.71% | 32.49% |
| Operating Income | 23.39% | 19.06% | 12.02% | -2.71% | -32.49% |
| Income Before Tax | 21.66% | 15.93% | 7.66% | -2.13% | -35.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.66% | 15.93% | 7.66% | -2.13% | -35.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.66% | 15.93% | 7.66% | -2.13% | -35.44% |
| EBIT | 23.39% | 19.06% | 12.02% | -2.71% | -32.49% |
| EBITDA | 23.84% | 19.59% | 12.45% | -2.43% | -32.72% |
| EPS Basic | 22.07% | 16.42% | 9.03% | 94.24% | 92.45% |
| Normalized Basic EPS | 22.07% | 16.43% | 9.05% | 94.24% | 92.45% |
| EPS Diluted | 22.07% | 16.42% | 9.03% | 94.24% | 92.45% |
| Normalized Diluted EPS | 22.07% | 16.43% | 9.05% | 94.24% | 92.45% |
| Average Basic Shares Outstanding | 0.52% | 0.59% | 1.51% | 1,672.66% | 1,692.76% |
| Average Diluted Shares Outstanding | 0.52% | 0.59% | 1.51% | 1,672.66% | 1,692.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |